Zoetis/$ZTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Ticker
$ZTS
Sector
Primary listing
NYSE
Employees
13,800
Headquarters
Website
Zoetis Metrics
BasicAdvanced
$66B
25.48
$5.82
0.89
$1.93
1.35%
Price and volume
Market cap
$66B
Beta
0.89
52-week high
$194.42
52-week low
$139.70
Average daily volume
2.9M
Dividend rate
$1.93
Financial strength
Current ratio
1.76
Quick ratio
0.889
Long term debt to equity
109.685
Total debt to equity
137.01
Dividend payout ratio (TTM)
32.08%
Interest coverage (TTM)
16.38%
Profitability
EBITDA (TTM)
3,946
Gross margin (TTM)
71.47%
Net profit margin (TTM)
27.83%
Operating margin (TTM)
37.52%
Effective tax rate (TTM)
20.98%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
15.37%
Return on equity (TTM)
52.77%
Valuation
Price to earnings (TTM)
25.475
Price to revenue (TTM)
7.09
Price to book
13.22
Price to tangible book (TTM)
57.51
Price to free cash flow (TTM)
29.987
Free cash flow yield (TTM)
3.33%
Free cash flow per share (TTM)
4.942
Dividend yield (TTM)
1.30%
Forward dividend yield
1.35%
Growth
Revenue change (TTM)
5.27%
Earnings per share change (TTM)
14.10%
3-year revenue growth (CAGR)
5.49%
10-year revenue growth (CAGR)
6.92%
3-year earnings per share growth (CAGR)
9.68%
10-year earnings per share growth (CAGR)
21.50%
3-year dividend per share growth (CAGR)
17.47%
10-year dividend per share growth (CAGR)
19.65%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Bulls say / Bears say
Zoetis delivered 8% organic operational revenue growth and 10% organic operational adjusted net income growth in Q2 2025, with reported net income up 15%, and raised its full-year revenue guidance to $9.45–$9.60 billion and adjusted EPS guidance to $6.30–$6.40, showing strong first-half performance (Reuters).
The companion animal segment posted 8% organic operational revenue growth to $1.79 billion in Q2 2025, lifted by strong demand for Simparica Trio and top dermatology products like Apoquel and Cytopoint (Reuters).
Zoetis reduced its 2025 adjusted cost of sales guidance to about 28.0% of revenue, down from 28.5%, indicating greater margin expansion potential from improved operational efficiency (Business Wire).
US livestock sales dropped 21% year-over-year and declined 2% on an organic operational basis in Q2 2025, mainly due to the sale of the medicated feed additive portfolio and supply timing issues, highlighting ongoing challenges in the production animal division (Business Wire).
Zoetis is facing stronger competition from Merck’s Numelvi and Elanco’s Zenrelia and CQ in important dermatology and parasiticide markets, with Stifel survey data pointing to increased veterinarian adoption of these competing therapies (Barron's).
Stifel Nicolaus downgraded Zoetis from Buy to Hold and reduced its price target, citing worries over slowing revenue growth through 2027 and stalled international expansion, indicating risks to the company’s near-term growth prospects (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Zoetis News
AllArticlesVideos
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
Business Wire3 days ago
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Business Wire3 weeks ago
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zoetis stock?
Zoetis (ZTS) has a market cap of $66B as of September 15, 2025.
What is the P/E ratio for Zoetis stock?
The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 25.48 as of September 15, 2025.
Does Zoetis stock pay dividends?
Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is $1.932 and the yield is 1.35%. Zoetis has a payout ratio of 32.08% on a trailing twelve-month basis.
When is the next Zoetis dividend payment date?
The next Zoetis (ZTS) dividend payment date is unconfirmed.
What is the beta indicator for Zoetis?
Zoetis (ZTS) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.